ISOFOL MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.695 SEK | +0.58% |
|
+0.14% | -4.79% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2021 | 22.41M 2.07M | Sales 2022 | 12.8M 1.18M | Capitalization | 120M 11.05M |
|---|---|---|---|---|---|
| Net income 2021 | -200M -18.49M | Net income 2022 | -160M -14.79M | EV / Sales 2021 | 49.7 x |
| Net cash position 2021 | 378M 34.92M | Net cash position 2022 | 187M 17.25M | EV / Sales 2022 | -5.24 x |
| P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.75
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.58% | ||
| 1 week | +0.14% | ||
| Current month | -4.66% | ||
| 1 month | -5.70% | ||
| 3 months | +10.49% | ||
| 6 months | -2.25% | ||
| Current year | -4.79% |
1 week
0.67
0.78
1 month
0.641.07
Current year
0.551.10
1 year
0.451.24
3 years
0.4514.44
5 years
0.4533.50
10 years
0.4533.50
| Managers | Title | Age | Since |
|---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.695 | +0.58% | 98,397 |
| 24-05-02 | 0.691 | -5.21% | 290,281 |
| 24-04-30 | 0.729 | -1.22% | 344,229 |
| 24-04-29 | 0.738 | +6.34% | 425,907 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotes
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Companyâs main shareholders are Biofol AB and Yield Life Science AB.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -4.79% | 10.39M | |
| +5.48% | 71.19B | |
| +12.55% | 9.3B | |
| -13.75% | 5.01B | |
| +42.38% | 4.47B | |
| +4.51% | 3.96B | |
| +21.10% | 2.44B | |
| -19.05% | 2.41B | |
| -28.72% | 2.23B | |
| +11.13% | 2.02B |
- Stock Market
- Equities
- ISOFOL Stock
